General Market Access Landscape for Remote Patient Monitoring in Europe

Current reimbursement landscape for remote patient monitoring in Europe

In Europe, reimbursement for remote patient monitoring varies by country, with most countries still developing reimbursement frameworks. Several European countries (Belgium, France, Germany, and the Netherlands) have established reimbursement models for remote patient monitoring, but the processes and conditions can differ significantly from one country to another.

France is the leader in remote patient monitoring from the reimbursement perspective in Europe. Since July 2023, when the new reimbursement framework called the List of Medical Telemonitoring Activities (LATM) replaced the national program for telemedicine “Experiments in Telemedicine for the Improvement of Health Pathways” (ETAPES program). LATM offers a structured reimbursement pathway for remote patient monitoring, expanding beyond the initial conditions covered under ETAPES. Under the LATM framework, two monthly lump-sum payments per patient are reimbursed: a fee for the healthcare provider overseeing the remote monitoring and a fee for the digital medical device operator supplying the necessary technology. Digital medical devices for remote patient monitoring are registered under six categories: digital medical devices for diabetes, cardiac diseases, respiratory diseases, chronic renal failure, oncology, and pain).

In Germany, remote patient monitoring services are reimbursed under the statutory health insurance system through specific codes in the Uniform Evaluation Standard (Einheitlicher Bewertungsmaßstab, EBM): for example, EBM code 03326 for remote monitoring in heart failure.

In the Netherlands, a new payment model for remote patient monitoring was debuted in 2023: telemonitoring is reimbursed as supplementary payment (OZP) under the category “Add-on – other” (code 039133) with a tariff of €185.63 (2025), defined by the Dutch Healthcare Authority (NZa) at the national level and paid on top of the DRG tariff. The procedure code 039133 can be registered and reimbursed once every 120 days. Remote monitoring of patients with multiple (chronic) conditions can be registered per condition, as it concerns different parameters and/or measured values for different medical specialties.

Role of HTA

Health Technology Assessment is an important factor influencing the adoption of remote patient monitoring, apart from reimbursement and acceptance by payers / national decision-makers. In most countries, HTA is incorporated into reimbursement decision-making (INAMI/RIZIV in Belgium, HAS in France, “New Methods” framework in Norway). However, in some countries, there are stand-alone HTA organizations whose recommendations can support the adoption of the new remote patient monitoring technologies by healthcare providers (NICE in England or AGENAS in Italy).

For example, in 2024, NICE released diagnostics guidance on algorithm-based systems for remote heart failure monitoring in people with cardiac implantable electronic devices (CIEDs). Two technologies received positive recommendations: HeartLogic and TriageHF, which should be used as options for algorithm-based remote monitoring in people with CIEDs who have heart failure. 

Future challenges 

Remote patient monitoring is gaining traction in Europe, but challenges related to reimbursement and funding may hinder its widespread adoption and long-term sustainability. There is no established reimbursement for remote patient monitoring in most countries.

Future challenges mostly include establishing a reimbursement framework for remote patient monitoring and expanding existing reimbursement frameworks to novel remote patient monitoring technologies or different indications for its application. HTAs and innovation funding schemes will play an important role in the future adoption of remote patient monitoring.